NCT06282874 is a Phase 4 clinical trial of Lorlatinib in Carcinoma, Non-Small-Cell Lung, sponsored by Guangdong Association of Clinical Trials.

Who is sponsoring NCT06282874?

NCT06282874 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT06282874?

Interventions in NCT06282874: Lorlatinib.

What condition does NCT06282874 study?

NCT06282874 studies Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis.

Is NCT06282874 still recruiting?

NCT06282874 is currently active, enrolled. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT06282874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Active, enrolled Phase 4 Last updated 9 April 2026

What this trial tests

Phase 4 trial testing Lorlatinib in Carcinoma, Non-Small-Cell Lung in 41 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2024

Primary endpoint
30 April 2026

1 March 2027

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	1 August 2024
Primary completion	30 April 2026
Estimated completion	1 March 2027
Sites	3 locations across China

Drugs / interventions tested

Lorlatinib (lorlatinib) — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Brain Metastases — all drugs for Brain Metastases →
Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →

Sponsor

Guangdong Association of Clinical Trials

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lorlatinib

Trials testing the same drug.

NCT07415005 — Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT06678555 — A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. · active not recruiting
NCT06487078 — Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World C · NA · recruiting
NCT06361589 — Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients · recruiting

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06282874 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing